stockrowAnteris Technologies Global Corp.
AVR Healthcare Medical Devices
Anteris Technologies Global Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 29.2% from fiscal 2024.
- Revenue
- +63.3%
- EPS
- +48.3%
- Free cash flow
- −6.84%
- Total debt
- +8.15%
Quarter to June 2026, against a year earlier
Follow AVR
Alert me
Anteris Technologies Global Corp. (AVR) EV/Sales
As of 6 November 2026, Anteris Technologies Global Corp. (AVR) trades at a EV/Sales of 131×. Over the past ten years it has ranged from 0.0× (December 2024) to 344× (July 2026); the current reading is higher than 73% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 89.7× | 469.87% |
| FY2024 | 15.7× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 313× | 225.14% |
| Mar 2026 | 96.3× | 7.30% |
| Dec 2025 | 89.7× | 25.21% |
| Sep 2025 | 71.7× | 63.50% |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TCMD Tactile Systems Technology, Inc. compare | 1.5× |
| CERS Cerus Corporation compare | 1.7× |
| CTKB Cytek Biosciences, Inc. compare | 2.2× |
| NPCE NeuroPace, Inc. compare | 4.5× |
| DCTH Delcath Systems, Inc. compare | 4.5× |
| MASS 908 Devices Inc. compare | 4.9× |
| SGHT Sight Sciences, Inc. compare | 5.6× |
| SENS Senseonics Holdings, Inc. compare | 8.3× |
| AVR Anteris Technologies Global Corp. | 128× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)